UCB (OTCMKTS:UCBJY) Sees Unusually-High Trading Volume – Still a Buy?

UCB SA (OTCMKTS:UCBJY) shares saw unusually-high trading volume on Tuesday . Approximately 26,955 shares changed hands during trading, a decline of 20% from the previous session’s volume of 33,632 shares.The stock last traded at $148.33 and had previously closed at $144.61.

Wall Street Analyst Weigh In

Separately, Wolfe Research raised UCB to a “strong-buy” rating in a research report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

UCB Price Performance

The stock’s 50 day simple moving average is $152.72 and its 200-day simple moving average is $143.35.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.